InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.72
(
-0.22%
)
Bitcoin
58,939.83
(
-2.03%
)
Post# of 2795
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12471
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: longx post# 2192

Saturday, 03/11/2017 1:38:18 PM

Saturday, March 11, 2017 1:38:18 PM

Post# of 2795
Longx, you have made some huge assumptions in your analysis that simply are not true.

See Dew's post:

"Only a tiny fraction of Xifaxan (rifaxamin) sales are in the acute-HE setting, which is an off-label indication for the drug."
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up